Overview

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Status:
Terminated
Trial end date:
2021-07-14
Target enrollment:
Participant gender:
Summary
This study is being conducted to demonstrate that perampanel given as adjunctive anti-epileptic treatment is superior to placebo in reducing the number of drop seizures in participants with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS).
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Inc.